Developer docs
API playgroundTry for free, no card

Search company profiles

Foli Bio

Full company profile

uuid002tbxs

Namestring
Foli Bio
Legal namestring
Foli Bio Inc.
Websiteurl
foli.bio
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Foli Bio is a privately held, early-stage biotech tools company founded in 2023 and headquartered in Long Island City, NY, that has built Foli-seq™, a non-invasive host gut transcriptomics platform profiling RNA from exfoliated gut epithelial and immune cells shed in routine stool samples. The platform is designed to surface mucosal inflammation, barrier function, tissue injury, repair, and therapeutic response biology without the invasiveness and episodic nature of endoscopic biopsy, the systemic-only signal of blood biomarkers, or the host-blindness of microbiome profiling. It is built on a peer-reviewed method published in Nature Biotechnology in 2025 and is anchored by a tiered panel architecture — human (Immune 500+ genes, Gut Function 1,800+ genes, Universal 11,000+ genes), matched murine panels, and companion animal (canine, feline) panels — supported by the Gut RNA Atlas, a proprietary host transcriptomic data platform that has accumulated 6,500+ profiled samples.

Foli Bio monetizes through three revenue streams: translational research services for pharma, biotech, and academic partners conducting biomarker discovery, pharmacodynamic monitoring, and preclinical-to-clinical translation; co-development of molecular diagnostics under milestone, licensing, and royalty economics (with screening and treatment-monitoring applications such as IBD activity, anti-TNF response prediction, and CRC/advanced adenoma screening); and data partnerships providing access to the Gut RNA Atlas. The company discloses 9 active pharma/biotech programs and 10+ academic/clinical collaborations, with Weill Cornell Medicine as a named academic anchor on the IBD Monitoring & Anti-TNF Response program. Pricing is not publicly disclosed and is structured per study or per partnership; distribution is exclusively direct B2B via business development outreach and website-driven inbound inquiries.

The company was co-founded by Harris H. Wang (Columbia University), Alejandro Chavez (UC San Diego), and Scott B. Snapper (Boston Children's Hospital / Harvard Medical School), and is supported by a capital stack of roughly $1.64M across Columbia Technology Ventures ($45K in 2023, $1.0M in 2024), NIH/NIDDK ($292K, 2024), NSF ($305K, 2025), NIH SEED, Empire State Development, Sky9 Capital, and a Bristol Myers Squibb Innovation Award. The current Foli-seq™ offering is explicitly limited to research and translational study applications and is not positioned for clinical diagnostic use.

Short descriptiontext

Foli Bio is a private biotech tools company providing Foli-seq™, a non-invasive stool-derived host RNA transcriptomics platform, to pharma, biotech, and academic research teams for biomarker discovery, pharmacodynamic monitoring, and molecular diagnostics co-development.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLong Island City, United States
HQ citystring
Long Island City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
host gut transcriptomics, non-invasive biomarker discovery, molecular diagnostics platform, stool RNA profiling, translational research services
Industry3 codes
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical and Diagnostic Laboratories6215
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Molecular Diagnostics Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Translational Research Services
TypeProfessional Services
Description

Revenue from providing Foli-seq™ profiling services to pharma, biotech, and academic research partners conducting biomarker discovery, pharmacodynamic monitoring, and preclinical-to-clinical translation studies. Services likely billed per sample or as study contracts.

2Clinical Diagnostic Development
TypeLicensing Royalties
Description

Co-development of molecular diagnostics with pharmaceutical and healthcare partners for disease monitoring, patient stratification, and CRC/advanced adenoma screening applications. Revenue model may include milestone payments, licensing fees, and commercial royalties.

foli.bio
3Data and Atlas Partnerships
TypeData Monetisation
Description

Partnerships for access to the Gut RNA Atlas data platform supporting precision medicine modeling, patient subtype discovery, and biomarker development. May include data access fees or collaborative research arrangements.

foli.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1Foli-seq™
Description

Non-invasive host gut transcriptomics platform that profiles host RNA from exfoliated gut epithelial and immune cells from stool samples, providing molecular readouts of mucosal inflammation, barrier function, disease biology, and therapeutic response. Includes tiered panels for human (Immune Panel 500+ genes, Gut Function Panel 1,800+ genes, Universal Panel 11,000+ genes), murine, canine, and feline studies.

foli.bio
Core offering1 text field

Foli Bio develops and delivers the Foli-seq™ platform, a non-invasive host gut transcriptomics technology that profiles host RNA from exfoliated gut epithelial and immune cells captured in routine stool samples, providing molecular readouts of mucosal inflammation, barrier function, tissue injury, repair, and therapeutic response. The offering is delivered as translational research services and molecular diagnostics co-development programs for pharmaceutical, biotechnology, molecular diagnostics, and academic research partners, supported by the Gut RNA Atlas data platform for precision medicine modeling and biomarker/target discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 43.4% sensitivity for advanced precancerous lesions reported for non-invasive stool-based test
+2 more records
Product overview1 text field

Foli Bio offers the Foli-seq™ platform — a non-invasive host gut transcriptomics platform that profiles host RNA from exfoliated gut epithelial and immune cells from stool samples. The platform comprises tiered panels across human (Foli-seq™ Human Immune Panel with 500+ genes, Human Gut Function Panel with 1,800+ genes, and Human Universal Panel with 11,000+ genes), murine preclinical models (Murine Immune Panel and Murine Gut Function Panel), and companion animals (Canine and Feline Core GI Host Panels with ~1,100 genes each). Supporting the platform is the Gut RNA Atlas, a transcriptomic data platform for precision medicine modeling. Together, these products enable translational biomarker studies, pharmacodynamic monitoring, patient stratification, and molecular diagnostics development across gastrointestinal disease areas.

Product and service5 records
1Foli-seq™ Platform
CategoryTranslational Research Services Platform
Description

Non-invasive host gut transcriptomics platform that profiles host RNA from exfoliated gut epithelial and immune cells captured in routine stool samples, providing molecular readouts of mucosal inflammation, barrier function, tissue injury, repair, and therapeutic response for translational research and diagnostics co-development customers.

2Foli-seq™ Human Panels
CategoryGene Panel Profiling
Description

Curated human gene panels ranging from targeted immune biology (500+ genes) and gut function profiling (1,800+ genes) to broad discovery profiling (11,000+ genes), used for biomarker discovery, patient stratification, responder prediction, and signature development in translational research customers.

3Foli-seq™ Preclinical (Murine) Panels
CategoryPreclinical Research Panels
Description

Matched murine panels (Immune Panel 500+ genes, Gut Function Panel 1,800+ genes) enabling cross-species host gut transcriptomic readouts in mouse models of gut inflammation, immune perturbation, microbiome intervention, and therapeutic response.

4Foli-seq™ Companion Animal Panels
CategoryVeterinary Research Panels
Description

Core GI host biology panels for canine and feline studies, profiling GI inflammation, epithelial injury, barrier function, repair biology, and treatment response in dogs and cats via non-invasive stool sampling.

5Gut RNA Atlas
CategoryData Platform
Description

Proprietary host gut transcriptomic data platform supporting precision medicine modeling, patient subtype discovery, biomarker and target discovery modeling, and multi-omic integration for data and precision medicine partners.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator on IBD Monitoring & Anti-TNF Response program. Weill Cornell Medicine partnership supports translational development of host transcriptomic signatures for IBD disease activity monitoring and anti-TNF response prediction.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic origin of Foli Bio. Scientific co-founder Harris H. Wang is Chair of the Department of Systems Biology at Columbia University. The company was co-founded with scientific leaders from Columbia's systems biology and genome engineering programs.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Academic collaborator supporting translational research programs. Mater Research partnership contributes to the growing research and innovation ecosystem backing Foli Bio.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaborator. Scientific co-founder Alejandro Chavez is Associate Professor in the Department of Pediatrics at UC San Diego, bringing expertise in genome engineering, functional genomics, and synthetic biology.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaborator. Clinical co-founder Scott B. Snapper is Chief of the Division of Gastroenterology at Boston Children's Hospital and Professor at Harvard Medical School, contributing expertise in gastroenterology, IBD, and mucosal immunology.

Strategic tierSecondaryTypeOthers
Description

Lab ecosystem partner providing laboratory space and infrastructure support for Foli Bio's operations.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Strategic partner contributing to Foli Bio's growing research and innovation ecosystem. Filgen partnership details not fully disclosed.

Strategic tierSecondaryTypeGTM or Marketing Partner
Description

Accelerator program membership providing mentorship, networking, and validation for life science tool innovators.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Personalis offers a tumor-informed molecular diagnostics platform (NeXT Personal) for minimal residual disease detection and other oncology applications. Both companies are molecular diagnostics developers with pharma co-development business models, though Personalis is blood/tumor-focused and further along in clinical commercialization.

TypeOthers
Description

Adaptive Biotechnologies commercializes immune repertoire sequencing (clonoSEQ, T-Detect) for clinical diagnostics and immune profiling. Both serve pharma with immune-related biomarker and translational services, but Adaptive's analyte is T-cell/B-cell receptor DNA rather than gut host RNA, making the connection thematic rather than directly competitive.

TypeDirect peer
Description

Freenome is a multi-omics blood-based cancer screening company whose first commercial indication is CRC. Both Foli Bio and Freenome pursue non-invasive molecular CRC screening with multi-analyte biomarker strategies, competing for the same clinical-decision-maker accounts and payor coverage.

TypeDirect peer
Description

Exact Sciences markets Cologuard, the leading non-invasive stool-based CRC screening test, and is the most direct competitor to Foli Bio's stool-based CRC/advanced adenoma screening program. Both companies target the same clinical question — non-invasive CRC detection — from a stool sample, but Exact Sciences uses DNA methylation while Foli Bio uses host RNA.

TypeBroad incumbent
Description

Guardant Health offers the Shield blood-based CRC screening test and a broad liquid biopsy oncology portfolio. While Guardant is a much larger incumbent and uses blood rather than stool, it is a directly comparable competitor in non-invasive CRC screening commercialization, payor engagement, and clinical guideline pursuit.

TypeBroad incumbent
Description

10x Genomics provides single-cell and spatial transcriptomics platforms (Chromium, Visium, Xenium) widely used in pharma biomarker discovery and translational research. Both companies enable transcriptomic profiling for translational pharma partners, but 10x is tissue/single-cell-focused and serves a much broader research market.

7Tempus AI
TypeEmerging player
Description

Tempus AI is a precision medicine data platform that aggregates molecular and clinical data for biomarker discovery and therapy decision support. It overlaps with Foli Bio's Gut RNA Atlas data-partnership revenue stream, as both monetize molecular data assets for pharma R&D, though Tempus operates at much larger scale across oncology broadly.

TypeDirect peer
Description

Geneoscopy is developing stool RNA-based colorectal cancer screening tests (ColoSense), making it the closest technical and product analog to Foli Bio. Both companies extract RNA biomarkers from stool samples for non-invasive CRC detection, validating Foli Bio's core thesis that stool RNA is a clinically informative analyte.

TypeBroad incumbent
Description

Bio-Techne is a large life-science tools company offering RNA/DNA reagents, gene expression assays (e.g., nCounter panels), and protein biology kits that compete with Foli-seq panels at the research-tools level. Both serve translational pharma/biotech biomarker discovery workflows, but Bio-Techne has a much broader catalog across many tissues and analytes.

TypeBroad incumbent
Description

NanoString (now part of Bruker) provides transcriptomics platforms including the nCounter Analysis System and GeoMx digital spatial profiling. Both companies sell gene-expression panel products to translational researchers, but NanoString's technology is tissue-based and broader in scope, while Foli Bio's is stool-based and gut-specific.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Foli Bio

Molecular Diagnostics Research Servicesfoli.bio

Foli Bio is a private biotech tools company providing Foli-seq™, a non-invasive stool-derived host RNA transcriptomics platform, to pharma, biotech, and academic research teams for biomarker discovery, pharmacodynamic monitoring, and molecular diagnostics co-development.

What Foli Bio does

Foli Bio is a privately held, early-stage biotech tools company founded in 2023 and headquartered in Long Island City, NY, that has built Foli-seq™, a non-invasive host gut transcriptomics platform profiling RNA from exfoliated gut epithelial and immune cells shed in routine stool samples. The platform is designed to surface mucosal inflammation, barrier function, tissue injury, repair, and therapeutic response biology without the invasiveness and episodic nature of endoscopic biopsy, the systemic-only signal of blood biomarkers, or the host-blindness of microbiome profiling. It is built on a peer-reviewed method published in Nature Biotechnology in 2025 and is anchored by a tiered panel architecture — human (Immune 500+ genes, Gut Function 1,800+ genes, Universal 11,000+ genes), matched murine panels, and companion animal (canine, feline) panels — supported by the Gut RNA Atlas, a proprietary host transcriptomic data platform that has accumulated 6,500+ profiled samples.

Foli Bio monetizes through three revenue streams: translational research services for pharma, biotech, and academic partners conducting biomarker discovery, pharmacodynamic monitoring, and preclinical-to-clinical translation; co-development of molecular diagnostics under milestone, licensing, and royalty economics (with screening and treatment-monitoring applications such as IBD activity, anti-TNF response prediction, and CRC/advanced adenoma screening); and data partnerships providing access to the Gut RNA Atlas. The company discloses 9 active pharma/biotech programs and 10+ academic/clinical collaborations, with Weill Cornell Medicine as a named academic anchor on the IBD Monitoring & Anti-TNF Response program. Pricing is not publicly disclosed and is structured per study or per partnership; distribution is exclusively direct B2B via business development outreach and website-driven inbound inquiries.

The company was co-founded by Harris H. Wang (Columbia University), Alejandro Chavez (UC San Diego), and Scott B. Snapper (Boston Children's Hospital / Harvard Medical School), and is supported by a capital stack of roughly $1.64M across Columbia Technology Ventures ($45K in 2023, $1.0M in 2024), NIH/NIDDK ($292K, 2024), NSF ($305K, 2025), NIH SEED, Empire State Development, Sky9 Capital, and a Bristol Myers Squibb Innovation Award. The current Foli-seq™ offering is explicitly limited to research and translational study applications and is not positioned for clinical diagnostic use.

Foli Bio firmographics

Firmographics
Name
Foli Bio
Legal name
Foli Bio Inc.
Website
https://foli.bio
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Foli Bio is a private biotech tools company providing Foli-seq™, a non-invasive stool-derived host RNA transcriptomics platform, to pharma, biotech, and academic research teams for biomarker discovery, pharmacodynamic monitoring, and molecular diagnostics co-development.
Ownership category
akta.pro rank

Foli Bio industry classification

Industry
Product category
Molecular Diagnostics Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)

Keywords

  • Host gut transcriptomics
  • Non-invasive biomarker discovery
  • Molecular diagnostics platform
  • Stool RNA profiling
  • Translational research services

Where Foli Bio is headquartered

Location

Headquarters

HQ city
Long Island City
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Foli Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Translational Research Services: Revenue from providing Foli-seq™ profiling services to pharma, biotech, and academic research partners conducting biomarker discovery, pharmacodynamic monitoring, and preclinical-to-clinical translation studies. Services likely billed per sample or as study contracts.
  2. Clinical Diagnostic Development: Co-development of molecular diagnostics with pharmaceutical and healthcare partners for disease monitoring, patient stratification, and CRC/advanced adenoma screening applications. Revenue model may include milestone payments, licensing fees, and commercial royalties.
  3. Data and Atlas Partnerships: Partnerships for access to the Gut RNA Atlas data platform supporting precision medicine modeling, patient subtype discovery, and biomarker development. May include data access fees or collaborative research arrangements.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Foli Bio product offering

Product offering

Core offering

Foli Bio develops and delivers the Foli-seq™ platform, a non-invasive host gut transcriptomics technology that profiles host RNA from exfoliated gut epithelial and immune cells captured in routine stool samples, providing molecular readouts of mucosal inflammation, barrier function, tissue injury, repair, and therapeutic response. The offering is delivered as translational research services and molecular diagnostics co-development programs for pharmaceutical, biotechnology, molecular diagnostics, and academic research partners, supported by the Gut RNA Atlas data platform for precision medicine modeling and biomarker/target discovery.

Product overview

Foli Bio offers the Foli-seq™ platform — a non-invasive host gut transcriptomics platform that profiles host RNA from exfoliated gut epithelial and immune cells from stool samples. The platform comprises tiered panels across human (Foli-seq™ Human Immune Panel with 500+ genes, Human Gut Function Panel with 1,800+ genes, and Human Universal Panel with 11,000+ genes), murine preclinical models (Murine Immune Panel and Murine Gut Function Panel), and companion animals (Canine and Feline Core GI Host Panels with ~1,100 genes each). Supporting the platform is the Gut RNA Atlas, a transcriptomic data platform for precision medicine modeling. Together, these products enable translational biomarker studies, pharmacodynamic monitoring, patient stratification, and molecular diagnostics development across gastrointestinal disease areas.

Differentiator

Problem solved

Functional benefit

Brands

  • Foli-seq™: Non-invasive host gut transcriptomics platform that profiles host RNA from exfoliated gut epithelial and immune cells from stool samples, providing molecular readouts of mucosal inflammation, barrier function, disease biology, and therapeutic response. Includes tiered panels for human (Immune Panel 500+ genes, Gut Function Panel 1,800+ genes, Universal Panel 11,000+ genes), murine, canine, and feline studies.

Products and services

  • Foli-seq™ Platform Non-invasive host gut transcriptomics platform that profiles host RNA from exfoliated gut epithelial and immune cells captured in routine stool samples, providing molecular readouts of mucosal inflammation, barrier function, tissue injury, repair, and therapeutic response for translational research and diagnostics co-development customers.
  • Foli-seq™ Human Panels Curated human gene panels ranging from targeted immune biology (500+ genes) and gut function profiling (1,800+ genes) to broad discovery profiling (11,000+ genes), used for biomarker discovery, patient stratification, responder prediction, and signature development in translational research customers.
  • Foli-seq™ Preclinical (Murine) Panels Matched murine panels (Immune Panel 500+ genes, Gut Function Panel 1,800+ genes) enabling cross-species host gut transcriptomic readouts in mouse models of gut inflammation, immune perturbation, microbiome intervention, and therapeutic response.
  • Foli-seq™ Companion Animal Panels Core GI host biology panels for canine and feline studies, profiling GI inflammation, epithelial injury, barrier function, repair biology, and treatment response in dogs and cats via non-invasive stool sampling.
  • Gut RNA Atlas Proprietary host gut transcriptomic data platform supporting precision medicine modeling, patient subtype discovery, biomarker and target discovery modeling, and multi-omic integration for data and precision medicine partners.

Quantifiable outcome

  • 43.4% sensitivity for advanced precancerous lesions reported for non-invasive stool-based test
  • +2 more outcomes

Companies that use Foli Bio

Customer profile

Segments4 records

Ideal customer profiles4 records

Foli Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Foli Bio partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and secondary.

  • Weill Cornell MedicinecoreStrategic or Co-development PartnerAcademic collaborator on IBD Monitoring & Anti-TNF Response program. Weill Cornell Medicine partnership supports translational development of host transcriptomic signatures for IBD disease activity monitoring and anti-TNF response prediction.
  • Columbia UniversitycoreStrategic or Co-development PartnerAcademic origin of Foli Bio. Scientific co-founder Harris H. Wang is Chair of the Department of Systems Biology at Columbia University. The company was co-founded with scientific leaders from Columbia's systems biology and genome engineering programs.
  • Mater ResearchsecondaryStrategic or Co-development PartnerAcademic collaborator supporting translational research programs. Mater Research partnership contributes to the growing research and innovation ecosystem backing Foli Bio.
  • UC San DiegocoreStrategic or Co-development PartnerAcademic collaborator. Scientific co-founder Alejandro Chavez is Associate Professor in the Department of Pediatrics at UC San Diego, bringing expertise in genome engineering, functional genomics, and synthetic biology.
  • Boston Children's Hospital / Harvard Medical SchoolcoreStrategic or Co-development PartnerClinical collaborator. Clinical co-founder Scott B. Snapper is Chief of the Division of Gastroenterology at Boston Children's Hospital and Professor at Harvard Medical School, contributing expertise in gastroenterology, IBD, and mucosal immunology.
  • BioLabssecondaryOthersLab ecosystem partner providing laboratory space and infrastructure support for Foli Bio's operations.
  • FilgensecondaryStrategic or Co-development PartnerStrategic partner contributing to Foli Bio's growing research and innovation ecosystem. Filgen partnership details not fully disclosed.
  • BioTools InnovatorsecondaryGTM or Marketing PartnerAccelerator program membership providing mentorship, networking, and validation for life science tool innovators.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Foli Bio competitors and assessment

Company assessment

Emerging players

  • Personalis: Personalis offers a tumor-informed molecular diagnostics platform (NeXT Personal) for minimal residual disease detection and other oncology applications. Both companies are molecular diagnostics developers with pharma co-development business models, though Personalis is blood/tumor-focused and further along in clinical commercialization.
  • Tempus AI: Tempus AI is a precision medicine data platform that aggregates molecular and clinical data for biomarker discovery and therapy decision support. It overlaps with Foli Bio's Gut RNA Atlas data-partnership revenue stream, as both monetize molecular data assets for pharma R&D, though Tempus operates at much larger scale across oncology broadly.

Others

  • Adaptive Biotechnologies: Adaptive Biotechnologies commercializes immune repertoire sequencing (clonoSEQ, T-Detect) for clinical diagnostics and immune profiling. Both serve pharma with immune-related biomarker and translational services, but Adaptive's analyte is T-cell/B-cell receptor DNA rather than gut host RNA, making the connection thematic rather than directly competitive.

Direct peers

  • Freenome: Freenome is a multi-omics blood-based cancer screening company whose first commercial indication is CRC. Both Foli Bio and Freenome pursue non-invasive molecular CRC screening with multi-analyte biomarker strategies, competing for the same clinical-decision-maker accounts and payor coverage.
  • Exact Sciences: Exact Sciences markets Cologuard, the leading non-invasive stool-based CRC screening test, and is the most direct competitor to Foli Bio's stool-based CRC/advanced adenoma screening program. Both companies target the same clinical question — non-invasive CRC detection — from a stool sample, but Exact Sciences uses DNA methylation while Foli Bio uses host RNA.
  • Geneoscopy: Geneoscopy is developing stool RNA-based colorectal cancer screening tests (ColoSense), making it the closest technical and product analog to Foli Bio. Both companies extract RNA biomarkers from stool samples for non-invasive CRC detection, validating Foli Bio's core thesis that stool RNA is a clinically informative analyte.

Broad incumbents

  • Guardant Health: Guardant Health offers the Shield blood-based CRC screening test and a broad liquid biopsy oncology portfolio. While Guardant is a much larger incumbent and uses blood rather than stool, it is a directly comparable competitor in non-invasive CRC screening commercialization, payor engagement, and clinical guideline pursuit.
  • 10x Genomics: 10x Genomics provides single-cell and spatial transcriptomics platforms (Chromium, Visium, Xenium) widely used in pharma biomarker discovery and translational research. Both companies enable transcriptomic profiling for translational pharma partners, but 10x is tissue/single-cell-focused and serves a much broader research market.
  • Bio-Techne: Bio-Techne is a large life-science tools company offering RNA/DNA reagents, gene expression assays (e.g., nCounter panels), and protein biology kits that compete with Foli-seq panels at the research-tools level. Both serve translational pharma/biotech biomarker discovery workflows, but Bio-Techne has a much broader catalog across many tissues and analytes.
  • NanoString (Bruker Spatial Biology): NanoString (now part of Bruker) provides transcriptomics platforms including the nCounter Analysis System and GeoMx digital spatial profiling. Both companies sell gene-expression panel products to translational researchers, but NanoString's technology is tissue-based and broader in scope, while Foli Bio's is stool-based and gut-specific.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Foli Bio social profiles

Digital presence

Foli Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Foli Bio leadership team

Management profile

Number of profiles

Profiles9 records

Foli Bio funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Foli Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Foli Bio

What does Foli Bio do?

Foli Bio develops and delivers the Foli-seq™ platform, a non-invasive host gut transcriptomics technology that profiles host RNA from exfoliated gut epithelial and immune cells captured in routine stool samples, providing molecular readouts of mucosal inflammation, barrier function, tissue injury, repair, and therapeutic response. The offering is delivered as translational research services and molecular diagnostics co-development programs for pharmaceutical, biotechnology, molecular diagnostics, and academic research partners, supported by the Gut RNA Atlas data platform for precision medicine modeling and biomarker/target discovery.

Is Foli Bio a public or private company?

Foli Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Foli Bio founded?

Foli Bio was founded in 2023. It employs 1 to 10 people.

Where is Foli Bio based?

Foli Bio is headquartered in Long Island City, United States, in the North America region.

How does Foli Bio make money?

Three revenue lines are on record. Translational Research Services are the primary driver. The others are clinical Diagnostic Development and data and Atlas Partnerships.

Who are Foli Bio's main competitors?

Emerging players on record are Personalis and Tempus AI. Adaptive Biotechnologies is listed as an others. Direct peers are Freenome, Exact Sciences and Geneoscopy. Broad incumbents are Guardant Health, 10x Genomics, Bio-Techne and NanoString (Bruker Spatial Biology).

Does Foli Bio have an API?

No public API is recorded for Foli Bio.

What industry is Foli Bio in?

Foli Bio's product category is Molecular Diagnostics Research Services. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 541714 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales